tradingkey.logo

MaxCyte Inc

MXCT
查看详细走势图
1.635USD
+0.135+9.00%
交易中 美东报价延迟15分钟
174.36M总市值
亏损市盈率 TTM

MaxCyte Inc

1.635
+0.135+9.00%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+9.00%

5天

+7.57%

1月

-2.10%

6月

-19.85%

今年开始到现在

-60.70%

1年

-61.44%

查看详细走势图

TradingKey MaxCyte Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

MaxCyte Inc当前公司基本面数据相对健康,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名105/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价6.34。中期看,股价处于平稳状态。近一个月,市场表现较差,但技术面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

MaxCyte Inc评分

相关信息

行业排名
105 / 208
全市场排名
242 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 7 位分析师
买入
评级
6.344
目标均价
+309.29%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

MaxCyte Inc亮点

亮点风险
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
业绩增长期
公司处于发展阶段,最新年度总收入38.63M美元
利润高增长
公司净利润处于行业前列,最新年度总收入38.63M美元
估值高估
公司最新PE估值-3.49,处于3年历史高位
机构减仓
最新机构持股82.96M股,环比减少17.02%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值9.86K
活跃度增加
近期活跃度增加,过去20天平均换手率0.71

MaxCyte Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

MaxCyte Inc简介

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
公司代码MXCT
公司MaxCyte Inc
CEOMasoud (Maher)
网址https://www.maxcyte.com/

常见问题

MaxCyte Inc(MXCT)的当前股价是多少?

MaxCyte Inc(MXCT)的当前股价是 1.635。

MaxCyte Inc的股票代码是什么?

MaxCyte Inc的股票代码是MXCT。

MaxCyte Inc股票的52周最高点是多少?

MaxCyte Inc股票的52周最高点是5.200。

MaxCyte Inc股票的52周最低点是多少?

MaxCyte Inc股票的52周最低点是1.260。

MaxCyte Inc的市值是多少?

MaxCyte Inc的市值是174.36M。

MaxCyte Inc的净利润是多少?

MaxCyte Inc的净利润为-41.05M。

现在MaxCyte Inc(MXCT)的股票是买入、持有还是卖出?

根据分析师评级,MaxCyte Inc(MXCT)的总体评级为买入,目标价格为6.344。

MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是多少

MaxCyte Inc(MXCT)股票的每股收益(EPS TTM)是-0.430。
KeyAI